Meeting
2021 Gastrointestinal Cancers Symposium
Genomic biomarker discovery of first-line gemcitabine/nabpaclitaxel treatment in Chinese advanced pancreatic carcinoma patients.
Authors
Juan Du
The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China
Juan Du , Qiuyue Pan , Huizi Sha , Zhengyun Zou , Weiwei Kong , Xin Qiu , Changchang Lu , Xin Zhang , Baorui Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Pancreatic Cancer
Track
Pancreatic Cancer
Sub Track
Other
Clinical Trial Registration Number
NCT03768687
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 436)
DOI
10.1200/JCO.2021.39.3_suppl.436
Abstract #
436
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.
First Author: Noura J. Choudhury
Poster
2022 ASCO Annual Meeting
Molecular characterization of long-term and short-term survivors of advanced pancreatic ductal adenocarcinoma.
First Author: Jesús Fuentes Antrás
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Devalingam Mahalingam